Orchard's Board of Directors oversees Orchard Therapeutics to ensure the company realizes our mission and vision.
Dr. Beck is currently the executive vice president of pharmaceutical development and operations and a member of the executive committee at Celgene.
Prior to Celgene, Dr. Beck was senior vice president of pharmaceutical development at Shire from 2012 to 2016. Before Shire, she held various leadership positions in Abbott’s global pharmaceutical operations and was the site head of Abbott Vascular Instruments GmbH. Earlier in her career, Dr. Beck held positions in process development at Genentech and Amgen. She holds a Bachelor of Arts degree from Lewis and Clark College and a Ph.D. from the University of Oregon Medical School.close profile
Marc Dunoyer is an independent board member at Orchard Therapeutics and chief financial officer at AstraZeneca. As a member of the senior executive team of AstraZeneca, Marc is responsible for managing the group’s financing strategy and governance. Marc joined AstraZeneca from GlaxoSmithKline (GSK) in 2013 as executive vice president, global portfolio & product strategy. At GSK, Marc served on the company’s corporate executive team and held positions as president for Asia-Pacific and Japan and foundational global head of GSK’s Rare Diseases Unit.
Marc has previously held international positions in operations and general management at Hoechst Marion Roussel and holds a Master of Business Administration degree from the Hautes Etudes Commerciales and a Bachelor of Law degree from Paris University.close profile
Jon Ellis is currently VP and Head of Science & Technology Licensing at GlaxoSmithKline. Over more than 25 years in the pharmaceutical and biotech industry, Jon has led a variety of R&D functions, drug development projects and strategic business development functions with a particular focus on complex technologies and emerging therapeutic modalities. He was responsible for many of GSK’s strategic transactions in the gene therapy field. Jon holds MA and PhD degrees from the University of Cambridge, and a MBA from Henley Management College. He is an inventor on more than 35 patent families.close profile
Bobby is Professor of paediatrics and immunology at the UCL Institute of Child Health and Honorary Consultant in paediatric immunology at Great Ormond Street Hospital, London.
He has a special interest in the treatment of severe primary immune deficiencies, including bone marrow transplantation, gene and cell therapy. He has led multiple clinical trials that have shown that gene therapy can successfully correct the genetic defect in immune deficiencies.
Bobby is currently leading UK and European-wide initiatives for newborn screening in severe combined immune deficiency. He is Director of the Centre for Research in Rare Diseases in Children (CRRDC), a new academic and clinical facility that will open at Great Ormond Street in 2018.close profile
Jim Geraghty is an industry leader with over 30 years of strategic and leadership experience, including more than 20 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. From 2013-16, Mr. Geraghty was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture and company-formation fund. He previously served as Senior Vice President, North America Strategy and Business Development at Sanofi, which he joined upon its acquisition of Genzyme. Mr. Geraghty spent over 20 years at Genzyme, where his roles included Senior Vice President International Development, President of Genzyme Europe, and the founding President and ceo of Genzyme Transgenics. Mr. Geraghty is chairman of the board of Idera, Pieris, and Juniper Pharmaceuticals, and is on the board of Voyager Therapeutics. He started his career in healthcare strategy consulting at Bain. A graduate of the Yale Law School, Mr. Geraghty also holds an M.S. from the University of Pennsylvania and a B.A. from Georgetown University.close profile
Alex Pasteur is a partner at F-Prime Capital based in London, UK. Alex earned a MA in Natural Sciences and a PhD in Chemistry from Cambridge University, and has worked in life sciences since 2001, covering investments in therapeutics and other healthcare sectors.
Alex joined F-Prime in 2012 and oversees the European portfolio that currently includes Orchard Therapeutics, Acacia Pharma Limited, Pulmocide Limited and Adaptimmune Therapeutics PLC (NASDAQ: ADAP). He previously worked at MVM Life Science Partners LLP in the USA and Europe and was responsible for investments in Cara Therapeutics Inc., Vantia Ltd and Xention Pharma Ltd.close profile
Mark is President and CEO of Orchard and brings 28 years of experience in the bio-pharmaceutical industry including driving the transition of multiple emerging biotechnology companies from R&D stage to commercialisation. During his career, he has focused on bringing novel therapies to market for patients with rare diseases, and has launched seven orphan drugs.
Prior to Orchard Therapeutics, Mark served as Chief Commercial Officer of PTC Therapeutics (“PTC”) where he helped transition the company from a privately funded, US-based R&D biotech to a public, commercial stage company with a 47 country commercialisation footprint. This he achieved by building a global commercialisation capability and successfully launching two rare disease therapies.
Prior to joining PTC, he served as Global President of Aegerion Pharmaceuticals Inc. and Vice President and General Manager of commercial operations at Shire Human Genetic Therapies for Europe, Middle East and Africa. Mark received an M.A. in Natural Sciences from Cambridge University and an MBA from INSEAD.close profile
Charles A. Rowland Jr. is a strategic advisor and board member for multiple biotechnology companies including Orchard Therapeutics, where he brings more than 30 years of biopharmaceutical industry experience. Charles was most recently the president and chief executive officer of Aurinia Pharmaceuticals, a clinical-stage pharmaceutical company focused on the global lupus nephritis market. Prior to Aurinia Pharmaceuticals, he served as vice president and chief financial officer of ViroPharma, during which time the company grew into a global biopharmaceutical rare diseases business before being acquired by Shire plc.
Charles has held finance, operational and executive positions at Endo, Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia, Novartis and Bristol-Myers Squibb and serves as a member of the board of directors for Blueprint Medicines, Nabriva Therapeutics, Viking Therapeutics and Psioxus Therapeutics. He holds a Master of Business Administration degree from Rutgers University and a Bachelor of Science from Saint Joseph's University.close profile
Simone Song is the founder and Senior Partner of ORI Capital and has over 25 years of experience in the healthcare sector. Prior to this, Simone held roles as Head of Goldman Sachs’ Healthcare Investment Bank and, in addition, she was the Managing Director of Cowen Group, a member of the advisory board of AXA Investment Managers and an executive board adviser to AXA Asia Pacific Holdings. Simone holds a Bachelor of Arts in Economics from Fudan University, China and a Master of Arts in Economics from Claremont Graduate School in the United States.close profile